M. Margeli Vila

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

R. Gelber, D. Larsimont, M. Buyse, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advantages of preoperative localization and surgical resection of metastatic axillary lymph nodes using magnetic seeds after neoadjuvant chemotherapy in breast cancer.

P. Rodríguez Martínez, M. Margelí Vila, A. Catanese, 2020, Surgical oncology.

LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial

B. González-Farré, T. Pascual, M. Espinosa-Bravo, 2022, Annals of Oncology.

SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

A. Prat, P. Villagrasa, B. González-Farré, 2021, Frontiers in Oncology.

202TiP SOLTI-1805 TOT-HER3 trial: A window-of-opportunity trial of patritumab deruxtecan (HER3-DXd) in patients with treatment-naïve, early breast cancer

B. González-Farré, T. Pascual, J. Guerra, 2022, Annals of Oncology.

Use of denosumab in a dialysis patient with bone metastases from breast cancer and hepatorenal polycystic disease: a case report

M. Margelí Vila, David López Sisamón, M. Hardy-Werbin, 2016, Anti-cancer drugs.

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

A. Lluch, S. González, R. Andrés, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

J. Herranz, A. Guerrero-Zotano, R. Bianco, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.

A. Ruíz, A. Lluch, S. González, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients

J. Herranz, A. Feber, M. Hubank, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.